SWOG Cancer Research Network

“Federal and Industry Sponsorship in US Cancer Clinical Trials,” Aug 20th in @jamaoncology.com. A comparative study of cancer clinical trial portfolios supported by federal versus industry funding characterizes their distinct, interdependent roles. doi.org/10.1001/jama...

Impressive! "A recent review of the SLAI portfolio identified 25 studies that have been approved for SLAI participation since 2020...From 2010 to 2019, only four SWOG studies had SLAI accrual, and generally, only one study was ever accruing at a time" @swog.org #SWOGonc More➡️ tinyurl.com/SLAIaug26

SWOG is 70 Years Strong! This year marks the 70th anniversary of the founding of the cooperative group that would go on to become the SWOG Cancer Research Network #SWOGonc @swog.org www.swog.org/.../2026/05/...

Lung-MAP investigators present 4 posters at #ASCO26. 1 is an analysis led by Dr. Diane Tseng of how the severity of immune-related adverse events (irAEs) in patients getting ICIs is associated with clinical outcomes: www.asco.org/abstracts-pr...

SWOG researchers give #ASCO26 oral presentations on results of 2 GI trials, a testicular cancer study, work on vit D & neuropathy, big-picture results from S1609 DART rare cancers trial, & an AI prediction model in breast cancer! @swog.org ASCO calendar is at swog.org/media/26051.

We want your great ideas! Our annual call for funding proposals has opened. Now through September 1, we welcome submissions from @swog.org members and collaborators #SWOGonc Learn more: conta.cc/4tSPFH3

Did you catch the recap from the @swog.org spring meeting? We made a big announcement honoring Dr. Blanke! (and there was cake 🍰) #SWOGonc www.swog.org/news-events/...

If you're here in San Francisco for the #SWOGonc meeting don't forget to leave a message for Dr. Blanke! Share a memory or best wishes for our @swog.org Group Chair Emeritus 🎉

Composition of Health Care Contact Days and Mortality Prediction Among Older Adult Clinical Trial Participants. Co-authored by Dr. Arjun Gupta; Cathee Till, MS; Michael LeBlanc, PhD; @drdawnhershman.bsky.social; @drjoeunger.bsky.social. @supportingswog.bsky.social ascopubs.org/doi/abs/10.1...

Apply by May 1: All #NCTN group members are eligible! @swog.org Virtual Grant Writing Workshop #SWOGonc conta.cc/3Qqnm4M

Thrilled and proud that our Hematology/Oncology Section Chief Dr. Smith has been selected as the Chair of @swog.org's lymphoma committee!! She is an incredible leader and very much deserves this honor!

"Lung-MAP is the most transformative & pivotal trial in the MET Crusaders right now." Hear MET Crusaders Chair Marcia K. Horn, JD, on 3 Lung-MAP studies for patients with advanced non-small cell #lungcancer with MET biomarkers. #lcsm #ClinicalTrials @focr.bsky.social www.youtube.com/watch?v=H1mx...

Team Hope showed up and gave it their all! 62 or 32 miles through the hills (and wind!) at the #TourDeScottsdale Every mile 🚴‍♀️ to advance @swog.org research #SWOGonc Proud of this crew! Grateful for everyone who donated & cheered us on 🙌 Watch the recap ⬇️ vimeo.com/1180550865?f...

A new chair for @swog.org 's lymphoma committee #SWOGonc "Please join us in welcoming Dr. Smith as chair of SWOG’s lymphoma committee, and in thanking outgoing chair Dr. Jonathan W. Friedberg for his visionary leadership of our lymphoma research effort." www.swog.org/news-events/...

S2409 PRISM is testing whether it’s feasible to identify each patient’s small cell #LungCancer subtype and use that information to select the best therapy for that patient. #SCLC Co-PI: Alberto Chiappori, MD @moffittnews.bsky.social swog.org/clinical-trials/S2409

Thank you to all riders, donors, and other supporters of @supportingswog.bsky.social and @swog.org in this event! And huge thanks to Dr. Parminder Singh for getting all of this rolling!

From the @swog.org Front Line: SWOG Establishes An APP & Nurse Scientist Committee #SWOGonc "Drs. Myers and Braun-Inglis are, of course, the ideal leadership team for this committee..." We agree! 💯 Congrats to this powerhouse team! www.swog.org/news-events/...

Blog post from SWOG chairs @drdawnhershman.bsky.social & Primo N. Lara, MD: SWOG Establishes An APP & Nurse Scientist Cmte Our new cmte recognizes the contributions of APPs to our success & will help empower more of them to contribute to their full scope of practice. www.swog.org/news-events/...

March 20, 2026: FDA approves nivolumab + AVD combination for Stage III or IV classical Hodgkin lymphoma in patients 12 and older, based on results of phase 3 S1826 #NCTN NCI trial, led by SWOG Cancer Research Network @swog.org and Children's Oncology Group (COG): www.fda.gov/drugs/resour...

Front Line post from @swog.org group chairs @drdawnhershman.bsky.social & Primo N. Lara, MD: The Next Era of SWOG Success In our vision, we focus even more intensively on studies that tackle the vital questions only public-powered research will answer. www.swog.org/news-events/...

Our @swog.org Chairs' blog: A Team Science Leadership Team SWOG is all about interdisciplinary collaboration and team science. We think a leadership approach with dual principal investigators who bring complementary skillsets and expertise to the role is a great fit. www.swog.org/news-events/...

Saying Thank You: Dr. Charles Blanke's last Front Line post as chair of @swog.org: "I have been honored to serve as chair of this research group over the last 13 years, and I could not be prouder of what you have accomplished in that time." www.swog.org/news-events/...

Follicular lymphoma has long been deemed incurable. New findings from a 15-year follow-up analysis of clinical trial patients with follicular lymphoma could upend that prediction. @mshadman.bsky.social @swog.org Read more: https://bit.ly/4rIb59x

At @ascocancer.bsky.social #GU26, results from @swog.org S1602 ph 3 trial to evaluate BCG strain differences & intradermal BCG priming in high-grade NMIBC: finds Tokyo BCG is non-inferior to TICE BCG & could mitigate BCG shortage. #BladderCancer In UroToday at www.urotoday.com/conference-h...

15-year results from @swog.org S0016 trial suggest follicular lymphoma is curable. Cure modeling estimates a 42% cure rate among S0016 patients. Relapse rates drop markedly over time. Study is in Feb 26 @jamaoncology.com @wilmotcancer.bsky.social @fredhutch.org jamanetwork.com/journals/jam...

Registration is open for SWOG's spring group meeting, April 30-May 2, in San Francisco! Incoming Group Chairs Drs. Primo Lara, Jr., & Dawn Hershman invite SWOG members to bring questions, concerns, & ideas to an interactive town hall-style plenary, Friday, May 1, 2-4pm PT. Details: swog.org/Sp26mtg

The latest @swog.org Front Line: A Cancer Research Agenda for the Nation, and for SWOG #SWOGonc www.swog.org/news-events/...

"Cancer statistics, 2026: Charting a course for a national cancer research agenda," commentary by Dr. Primo Lara, Jr, & @drdawnhershman.bsky.social publ w the annual portrait of U.S. #cancer stats in CA: A Cancer Journal for Clinicians, just out! #NCTN #NCORP @eaonc.bsky.social @nrgonc.bsky.social

S2213 is a randomized ph 3 to definitively learn role of transplant in pts newly diagnosed w AL #amyloidosis. BMT-CTN Champion: Anita D'Souza, MD SWOG.org/clinical-trials/S2213

Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT). SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC

Extensive stage small cell lung cancer can be hard to treat — but study S2409 (the PRISM trial) is looking for better, personalized options. To learn more, visit SWOG.org/S2409 or call 1-800-4-CANCER. #LCSM #SCLC

S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.

For all #SWOGonc early career GU researchers: The Nicholas Vogelzang GU Scholars Program Includes mentorship and travel support - apply by January 15 w/ @swog.org thehopefoundation.org/vogelzang-gu...

#ClinicalTrial S2409 (PRISM) asks if it’s possible to personalize treatment for extensive stage small cell lung cancer. It compares standard treatment alone to standard treatment plus a drug matched to the cancer subtype. Learn more: SWOG.org/S2409 or 1-800-4-CANCER.

Have you had treatment for muscle invasive #BladderCancer? Are you expecting surgery next? If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT). Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation

In a multi-trial analysis led by Fred Hutch's Dr. Joe Unger, patients reporting fatigue prior to systemic cancer treatment faced 2x the risk for severe toxic effects and nearly 5x the risk for fatal complications compared with those with minimal to no fatigue. @swog.org https://wb.md/3LozLE8

Just activated! #NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm PI: Rachael A. Safyan, MD @fredhutch.org swog.org/clinical-tri...

In @jamaoncology.com: higher baseline fatigue assoc w higher risk of severe #cancer treatment-related toxic effects. Initial fatigue assessment may be early marker of risk for SAEs & inform personalized therapy. @drjoeunger.bsky.social @drdawnhershman.bsky.social @fischmd.bsky.social @fredhutch.org

S2213 is a randomized ph 3 to definitively learn the role of transplant in pts newly diagnosed w AL #amyloidosis. ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD SWOG.org/clinical-trials/S2213

Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC

Our program offerings kick off right away in 2026. #SWOGonc members, please don't miss our January 15 deadline for CRA and nurse travel to the spring @swog.org group meeting! thehopefoundation.org/funding-oppo...

If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t started initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC

Study S2213 asks if a drug combination known as Dara-VCD or stem cell transplant is better for treating AL #amyloidosis. It tests how well the treatments work, and how they affect quality of life. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease #clinicaltrial

Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials doi.org/10.1158/1078...

#ClinicalTrial S2409 PRISM randomizes patients with extensive stage small cell lung cancer to durvalumab with or without a drug that’s targeted to their specific #SCLC subtype. Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center swog.org/clinical-trials/S2409

S2427 BRIGHT trial tests IO + RT as bladder-preserving tx for patients with MIBC who respond to NAT. PROs track QoL and treatment-related symptomatic toxicities. Systematic biopsies needed at post-NAT TURBT. Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center swog.org/clinical-trials/S2427

If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t finished initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC

Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC